Over the last three years, the Cure Parkinson’s research team and a group of Parkinson’s advocates have produced an annual report outlining the current development pipeline of new drug-based treatments for Parkinson’s. The 2022 version of this report has been published.

Despite the difficulties imposed by the ongoing COVID-19 pandemic, clinical trials focused on developing potential new treatments for Parkinson’s are proceeding. This is largely thanks to the committed efforts of both the researchers and the trial participants. Our recent report of the development of new drugs for Parkinson’s found that in 2021, there were 147 active clinical trials. 91 of these, or 62%, were evaluating symptom treatments, while 56, or 38%, of these trials were testing potentially disease-modifying treatments for Parkinson’s.

Of the 147 active clinical trials, 51, or 35%, of these trials were in the early phase 1 stage, being tested in people for the first time – usually testing the drug’s safety and tolerability. 74 of the clinical trials, roughly half, were in phase 2 testing, usually to test evidence of the efficacy of the drug. The final phase 3 stage accounted for 22 of these clinical trials, or 15%, testing both the safety and the efficacy of these treatments in a very large group of people. Importantly, out of 56 potentially disease-modifying treatments, only three were in the final phase 3 stage – one being the ‘Exenatide PD3 study’ supported by Cure Parkinson’s.

When compared to previous years (2019 and 2020), there has been little increase in the overall number of clinical trials taking place. Cure Parkinson’s is endeavouring to increase the number of clinical trials of disease-modifying treatments in phase 3 in the very near future.

How helpful was this content?

/ 5. Vote count:

We are sorry that this content was not useful for you

Let us improve this content

Can you tell us how we can improve this content?